About this episode
This week, we round out our discussion on the early stage breast cancer, turning our attention to the triple negative subtype. Once again, there are a lot of trials and data, but be sure to check out the show notes for the highlights! Content: - What is TNBC? -What is the data to support the use of neoadjuvant therapy in this disease? - What is "pathologic CR" and how is different than "residual cancer burden"? - Can we ever omit neoadjuvant therapy? - What are our options for chemotherapy regimens in neoadjuvant and adjuvant setting? ** This episode has been sponsored by HemOnc.org ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Google Podcast